Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer： a series of 20 cases

摘要

The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer.We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer.The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m2 in weekly schedule.Cumulative findings showed that the overall response rate was 30.0%,the disease control rate amounted to 40%,and the 1 year survival rate was 30%.In addition,the median time to progression and the median survival time reached 5 and 10 months,respectively.Meanwhile,no severe hypersensitivity reactions and grade 4 adverse effects were reported.In summary,weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy.